Patent ID: 6936416

Claim:
A method of determining the stage of disease caused by HCMV infection, comprising the step of: determining expression levels in a first human cell sample of a set of genes comprising M24594, Interferon stimulated genes 54K; M87434, 71 kDa 2′5′ oligoadenylate synthetase; X02875, (2′-5′) oligo A synthetase E (1.8 kb RNA); X02874, (2′-5′) oligo A synthetase E (1.6kb RNA); M87284, 69 kDa 2′5′ oligoadenylate synthetase; X02530, gamma-interferon inducible early response gene; L05072 Interferon regulatory factor 1 (IRF-1); X5949, Interferon regulatory factor 2 (IRF-2); X67325, Interferon-alpha inducible gene, p27 gene; H05300, Interferon-induced guanylate-binding protein 1; M55542, guanylate binding protein isoform II; D31887, KIAA0062 (cig 19); X88220, interferon inducible gene staf50; X02492, interferon-induced protein 6-16; R34698, interferon-inducible protein 9-27; M13755, interferon-induced 17 kDa/15 kDa protein; M28622, interferon beta; X17668, indoleamine 2,3-dioxygenase; M33882, MxA; M30818, MxB; X56841, HLA-E gene; T50250, est: homo to U51904, mouse IFN α-treated mRNA; M60618, nuclear autoantigen Sp100; M73778, PML-1; R39857, est=X97630—serine/threonine protein kinase EMK; H02889, est=Y11366 IMPA gene; U25994, cell death protein (RIP protein kinase); D21209, protein tyrosine phosphatase (PTP-BAS type 1); X77278, HYL tyrosine kinase; R60908, est=X74764—receptor protein tyrosine kinase; H65441, est=U78027, L35265—Bruton's tyrosine kinase; and X16416, proto-oncogene tyrosine-protein kinase (abl), wherein the first human cell sample consists essentially of HCMV-infected cells of a patient infected with HCMV, wherein the expression levels of one or more genes of the set of genes correlates with stage of disease progression of the HCMV infection; and determining a stage of disease progression based on the expression levels.